| Pioneer Foot And Ankle, Pllc | |
|
3300 N Running Creek Way, Building C Suite 300, Lehi, UT 84043 | |
| (801) 631-7997 | |
| Not Available |
| Full Name | Pioneer Foot And Ankle, Pllc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 3300 N Running Creek Way, Lehi, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144085093 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Pioneer Foot And Ankle, Pllc 3300 N Running Creek Way, Building C Suite 300, Lehi, UT 84043-3182 Ph: (801) 901-4333 | Pioneer Foot And Ankle, Pllc 3300 N Running Creek Way, Building C Suite 300, Lehi, UT 84043 Ph: (801) 631-7997 |
News Archive
NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and a leading provider of healthcare information systems and connectivity solutions, today announced that it has partnered with Allina Hospitals & Clinics to foster better patient care coordination among physician practices of all sizes in Minnesota and Western Wisconsin.
Using carbon nanotubes linked to tumor-homing antibodies, a research team headed by Ellen Vitetta, Ph.D., M.D., of the University of Texas Southwestern Medical Center has shown that they can specifically kill the targeted tumor cells using near-infrared light. This work appears in the Proceedings of the National Academy of Sciences.
Irritable Bowel Syndrome is a common gastrointestinal disorder affecting 10 - 20 per cent of people. Abdominal pain, bloating and altered bowel habit significantly affect patients' quality of life and can force them to take days off work.
BioMimetic Therapeutics, Inc., announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share.
Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration.
› Verified 3 days ago
Wade A Christiansen, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 179 N 1200 E Ste 103, Lehi, UT 84043 Phone: 801-995-0898 Fax: 801-766-6022 |